Q Fever and Auto-immunity

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Completed

Conditions: Q Fever; Auto-Immunity

Treatments: Biological: Blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT02822807

2013-A00963-42 (Other Identifier)

2013-31

Details and patient eligibility

About

The IHU Mediterranean infection is national reference centre for Q fever. Coxiella burnetii is the bacteria responsible of this infection. The bacterium Coxiella burnetii infection is associated with secretion by the body both many antibodies against the bacteria but also against certain cells of the body (autoantibodies). These autoantibodies may have no effect or be associated with specific symptoms. Anti-Phospholipid antibodies are especially prevalent in the Q fever. Apart from this infection, they are associated with thrombocytopenia, obstetric complications, thrombosis and heart valve damage. These conditions have also been described as complications during Q fever. In a retrospective preliminary work on Q fever, we have shown that the presence of high levels of IgG anti-cardiolipin was associated with the presence of valvular and the evolution to endocarditis. Such associations have a therapeutic involvement and must therefore be confirmed. Indeed, if these associations were confirmed, a trans-esophageal ultrasound could be systematically proposed to patients with valvular disease of trans-thoracique ultrasound but IgG anticardiolipin high levels. Other special attention could be given to patients with high autoantibodies.

Enrollment: 300 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a current or former Q fever diagnosis
• Patient > or = 18 years old.
• Patient who does not declined to have his medical records reviewed for research.
• Patient with health insurance.

Exclusion criteria

• Minor patient (<18 years )
• Adult patient under guardianship .
• Patient deprived of liberty or judgment.
• Patient refusing to sign the informed consent form .

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

300 participants in 4 patient groups

Q fever without valvular disease

Other group

Description:

Q fever without valvular disease

Treatment:

Biological: Blood sampling

Q fever with valvular disease

Other group

Description:

Q fever with valvular disease

Treatment:

Biological: Blood sampling

Q fever infective endocarditis

Other group

Description:

Q fever infective endocarditis

Treatment:

Biological: Blood sampling

Other Coxiella burnetii infections (including pregnant women)

Other group

Description:

Other Coxiella burnetii infections (including pregnant women)

Treatment:

Biological: Blood sampling